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Abstract: Myocardial contrast echocardiography (MCE) is a relatively simple myocardial perfusion imaging technique 
which should be used in different clinical settings. The ability of MCE to provide a comprehensive assessment of cardiac 
structure, function, and perfusion is likely to make it the technique of choice for non-invasive cardiac imaging. 
Contrast agents are encapsulated microbubbles (MB) filled with either air or high-molecular-weight gas. They are 
innocuous, biologically inert and when administered intravasculary, the sound backscatter from the blood poll is enhanced 
because MB have the enormous reflective ability due to a large acoustic impedance mismatch between the bubble gas and 
surrounding blood. 
MCE is an ideal imaging tool for the assessment of left heart contrast and the myocardial microcirculation. MCE detects 
contrast MB at the capillary level within the myocardium and, thus, has the potential to assess tissue viability and the 
duration of the contrast effect. MCE was equivalent to SPECT for the detection of CAD with a tendency toward higher 
sensitivity of MCE compared with SPECT in microvascular disease and CAD. MCE is also a bedside technique that can 
be used early in patients presenting with acute heart failure to rapidly assess LV function (regional and global) and 
perfusion (rest and stress). 
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  The MB are smaller than the capillaries and should flow 
freely through the coronary circulation. It is important to 
remember that the actual risk associated with contrast is very 
small, especially if physician follow the contrast adminis-
tration recommendations that suggest avoiding the use of 
MB in unstable and critically acute ill patients. 
PHYSICAL CHARACTERISTICS OF CONTRAST 
AGENT 
  Contrast agents are encapsulated microbubbles (MB) 
filled with either air or highmolecular-weight gas. They are 
innocuous, biologically inert and when administered intra-
vasculary, the sound backscatter from the blood poll is 
enhanced (non-linear acoustic behaviour) because MB have 
the enormous reflective ability due to a large acoustic 
impedence mismatch between the bubble gas contenent and 
surrounding blood. 
  The ability of MB to produce strong backscattered 
acoustic signal is based on their compressibility, which 
depends on the viscoelastic and pressure properties of the 
shell and gas. MB encapsulation is required to increase 
stability and persistence, which depends on rigidity and 
provides persistence and good resistance to blood pressure 
changes and US pressure waves. A degree of fragility is 
needed to allow the destruction and posterior myocardial 
refilling. Another approaches to extend MB survival are the 
use of gas with low solubility and diffusibility. 
*Address correspondence to this author at the Department of Internal 
Medicine, University of Genoa, Viale Benedetto XV 6 16132 Genoa, Italy 
Tel: ++39 010 353 7934; Fax: ++39 010 353 8994;  
E-mail: gian.paolo.bezante@unige.it 
  The diameter of MB is one of the major determinants of 
scattering behavior because the scattering cross section is 
extremely dependent on the bubble size and is directly 
proportional to the sixth power of its radious [1]. Larger MB 
produces higher US signal and any reduction in the size 
results in a marked decrease of its reflection ability. The 
range diameter is from 1 to 10 μm, and the ideal size is 
approximately 4 μm (Table 1). The signal intensity depends 
on MB concentration: at low concentration the signal 
intensity increase linearly; as the concentration increases, the 
relationship between MB and signal intensity becomes 
curvilinear until it reach a plateau, where the contrast effect 
may actually decrease. 
  The interaction between MB and US produces 
compression during pressure peaks and expansion during 
pressure nadirs. It appears a remarkable and fortuitous 
coincidence that gas bubbles of a size required to cross the 
pulmonary capillary vascular resonate in a frequency range 
of 1.5–7 MHz, precisely that used in diagnostic US echo-
cardiography. The oscillation of MB may produce a wide 
range of harmonic frequencies: subharmonic [2, 3], second 
harmonic, ultraharmonics [4] and super harmonics (third, 
fourth, fifth). The harmonic response is dependent upon the 
physical characteristics of the agent (both size and 
mechanical properties), the incident pressure of the US field, 
and the frequency [5]. In particular, the responce of MB 
depend also about their mechanical index (MI). MI is 
defined as the peak of negative pressure divided by square 
root of the US frequency. Unlike solid tissue, gas bubbles 
have acoustic properties that vary with the strength of the 
insonating signal. With increasing power, insonation of gas 
bubbles can result in linear oscillation (MI<0,1), non-linear Potential Clinical Application on Contrast Echocardiography  Current Cardiology Reviews, 2010, Vol. 6, No. 1    25 
oscillation (MI 0,1-1,0) or bubble destruction (MI>1,0 
scintillation) [6, 7]. 
CLASSIFICATION 
  The first agents capable of left heart contrast after intra-
venous injection (first generation agents) were air bubbles 
stabilised by encapsulation (Albunex)
® or by adherence to 
microparticles (Levovist)
®. Replacing air with a low solu-
bility fluorocarbon gas stabilises bubbles still further (second 
generation agents—for example, Optison, SonoVue)
®, 
greatly increasing the duration of the contrast effect. Third 
generation agents—not yet commercially available—will use 
polymer shell and low solubility gas and should produce 
much more reproducible acoustic properties. These 
properties allow passage of the pulmonary vasculature, 
opacification of the left ventricular cavity, and imaging of 
myocardial perfusion. Currently, the most used second-
generation contrast agents are Sonovue
® (Bracco, Milan, 
Italy), Optison
® (Amersham Health AS, Oslo, Norway), and 
Definity
® (Bristol-Myers Squibb, Billerica, Massachusetts) 
(Table  1). These agents differ in terms of their shell 
constituents and gas content that influence shell-stiffness and 
stability of the MB, and determine physical properties [8]. 
Even if these agents are licensed for left ventricular 
opacification only, all are suitable for myocardial perfusion. 
IMAGING MODALITIES TO ASSESS MICRO-
CIRCULATION 
  Myocardial contrast echocardiography (MCE) is an ideal 
imaging tool for the assessment of the myocardial micro-
circulation. MCE detects contrast MB at the capillary level 
within the myocardium and, thus, has the potential to assess 
tissue viability. At baseline, approximately 8% of left 
ventricular mass is constituted by blood present in the 
microcirculation termed myocardial blood volume (MBV), 
90% of which is comprised of blood in the capillaries. In 
normally perfused myocardium, the rate of capillary blood 
flow is 1 mm/s. Saturation of the coronary microvasculature 
by MB therefore takes about 5 s (because the thickness of 
the US beam is approximately 5 mm). When there is no flow 
limiting stenosis, MBF increases 5 times during hyperemia 
(stress testing), and therefore the myocardium replenishes in 
1 s. In addition, a flow-limiting stenosis leads to a reduction 
in capillary blood volume in the distal microvasculature, 
with an accompanying decrease in signal intensity during 
MCE. These 2 features (slowed contrast appearance and 
decreased capillary blood volume) form the basis for 
detecting CAD using MCE. However, because the US beam 
used to detect the MB also destroys them at normal power 
outputs, the lower the MBF the longer the time required to 
achieve peak video intensity. 
  The mechanism of US images enhancement depends on 
MB’behavior under acoustic pressure. The enormous 
reflective ability of MB is due to a large acoustic impedence 
mismatch between the bubble gas content and the surroun-
ding blood. In contrast to MB, cardiac tissue produces much 
fewer harmonic frequencies, so selective reception of 
harmonic echos will preferentially detect signals emanating 
from contrast agent rather than the myocardium. Although 
these methods improved the signal-to-noise ratio, off-line 
Table 1.  Principal Parameters of MCE 
 Definity  Optison  Sonovue 
Composition  Perflutren lipid microsphere  Perflutren protein-type A  Sulphur hexafluoride in form of MB 
Company  Bristol-Myers Squibb  Amersham Health AS  Bracco Imaging 
Shell composition  Lipid  Albumin  Lipid- no shell  surfactant stabilized 
Mean diameter  (μm)  1,1-3,3   3,0-4,5  2,5 
Range  % less than 10 μm is 98%; maximum 
diameter 20 μm 
% less than 10 μm is 98%; maximum 
diameter 32 μm 
% less than 11 μm 99%; maximum 
diameter 20 μm 
Metabolism  Stable gas not metabolized. 
Phospholipid component are 
metabolized to free fatty acids.  
Stable gas not metabolized. Albumin 
handled by the normal metabolic route.  
Sulphur exafluoride dissolves in the 
blood and is subsequently exhaled. 
Elimination  By lungs; not detectable in the blood 
or expider air after 10’ 
By lungs; not detectable in the blood or 
expider air after 10’ 
By lungs; not detectable in the blood or 
expider air after 15’ 
Bolus  10 mL/Kg iv bolus injection whitin 
30-60sec, followed by 10mL of saline 
flush. 
0.5 mL iv.  This may be repeated for further 
contrast  enhancement. 
2 or 2.4 ml and might be repeated. 
Every injection should be followed by 
saline flush. 
Infusion  1,3 mL added to 50 mL saline; rate of 
infusion should be initiated at 4.0 
mL/min, but titraded as necessary 
The injection rate should not exceed 1 mL 
per second, followed by a saline flush. 
at 50 to 70 mL/h with VueJect (BR-INF 
100,Bracco Research SA) 
Maximun dosage  Not exceed 10 mL/min. The 
maximum dose is either low bolus 
doses or one single iv infusion.  
Not exceed 5.0 mL in any 10 minute period. 
The maximum total dose should not exceed 
8.7 mL in any one patient study.  
In a Phase I study doses up to 56 ml of 
SonoVue were administered to normal 
volunteers without serious adverse 
events being reported.  26    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Bezante et al. 
image processing is frequently required to evaluate 
myocardial perfusion, because tissue signals is still present. 
Harmonic imaging also used high acoustic powers that 
destroyed MB consequently, the imaging frame rate had to 
be reduced substantially with electrocardiographic triggering 
to allow MB to replenish the myocardial microcirculation 
between pulses (Table 2). 
  These include high-power modalities with superior tissue 
noise suppression that allow on-line assessment of 
myocardial perfusion and low-power modalities that permit 
imaging with high frame rates. These modalities specifically 
take advantage of the nonlinear behavior of MB in an 
acoustic field. Many techniques use multiple transmitted 
pulses that are, e.g. full and half amplitude (power modu-
lation imaging, Fig. (1). to distinguish nonlinear MB signals 
from tissue. Reflected echos are scaled and subtracted. 
Because tissue responds linearly (especially at low acoustic 
powers), subtraction and scaling results in zero signal. MB 
reflect nonlinearly, so received echos will not be canceled 
out, enabling selective MB detection. Most of these 
multipulse techniques additionally use power Doppler, and 
the resulting signal is color coded and displayed. Because 
high-power imaging destroys MB, imaging of myocardial 
perfusion cannot be performed in real time. Low MI imaging 
increases signal-to-noise ratio and because of minimal MB 
destruction continuous imaging may be performed. Both 
high- and low-power MCE have their advantages and 
disadvantages. High-power imaging precludes continuous 
imaging owing to destruction of contrast, and therefore wall 
motion cannot be assessed simultaneously. On the other 
hand, signal-to-noise ratio is good. Low-power imaging 
allows simultaneous assessment of perfusion and contraction 
but has a lower sensitivity for the detection of MB.  
MYOCARDIAL PERFUSION: DEFINITION AND 
RILEVANCE 
  Myocardial perfusion imaging is a functional cardiac 
imaging, used for the diagnosis of ischemic heart disease [9]. 
The underlying principle is that under conditions of stress, 
diseased myocardium receives less blood flow than normal 
myocardium. This method needs a inert myocardial tracer, 
that injected in a peripheral vein, is able to reach the 
coronary vascular bed and a cardiac imaging system devoted 
to detect normal or abnormal myocardial distribution of the 
tracer during rest and stress conditions. Following this, the 
heart rate is raised to induce myocardial stress, either by 
exercise or pharmacologically with adenosine, dobutamine 
or dipyridamole (aminophylline can be used to reverse the 
effects of dipyridamole). Imaging techniques performed after 
stress reveals the distribution of the tracer, and therefore the 
relative blood flow to the different regions of the myo-
cardium. Diagnosis is made by comparing stress images to a 
further set of images obtained at rest. Nuclear myocardial 
perfusion studies are the most utilized imaging techniques to 
evaluate myocardial perfusion, while an image technique as 
MCE that could simultaneously detect wall motion and 
measure perfusion was indeed the holy grail of coronary 
artery disease (CAD) testing is still potential toll under 
evluation mainly due to safety issues. Contrast echocardio-
graphy is a potential technique to evaluate myocardial 
perfusion. A cardiac specific radiopharmaceu-tical (E.g. 
99mTc-tetrofosmin-Myoview®, GE healthcare, 99mTc-
sestamibi-Cardiolite®, Bristol-Myers Squibb) or a micro-
bubble contrast agents like Optison®, Definity® or 
SonoVue® should be administered. 
SAFETY OF CONTRAST AGENT 
  MB can potentially affect the heart by mechanical 
obstruction of the coronary vessels or cause direct cell 
damage when destroyed in high-intensity sound fields. 
Mechanical obstruction can occur when bubbles larger than 
capillary diameter are injected into the coronary circulation. 
However, the bubbles are generally smaller than the 
capillaries and should flow freely through the coronary 
circulation. Even without a specific mechanism, the fatal 
aderse events in unstable patients suggest that increased 
caution is appropriate. First, it is important to remember that 
the actual risk associated with contrast is very small. Second, 
the new list of contraindications for encapsulated MB 
contrast agents (Table 3) would preclude most applications 
in the intensive care unit/critical care unit. Likewise the 
recommendation that patients be monitored for 0.5 h after 
injection will limit use in portable studies on nonmonitored 
hospitalized patients and, in many laboratories will 
complicate outpatient studies. This would only require 
extension of the postprocedure monitoring [10, 11]. These 
new warnings also raise the issue of informed consent. 
  While there is no doubt that the use of contrast enables 
acquisition of US images of improved quality, these setbacks 
in contrast agent safety are not the only problem. There has 
been slower than expected adoption of their use, whether due 
to low reimbursement or the "hassle factor" of an intra-
venous medication, and no agent has yet been approved for 
myocardial perfusion. In the end, these new warnings do not 
Table 2.  Contrast Specific Imaging Methods for Assessment of Myocardial Perfusion 
  Harmonic B-mode  Harmonic power Doppler  Pulse invertion  Power pulse invertion 
Bubble-to-tissue sensivity  Moderate  Very good  Good  Very good 
Off-line background subtraction 
needed 
Yes No Yes  No 
LV-myocardium delineation  Poor  Good  Moderate  Good 
Wall motion artifacts  None  Can be severe  Moderate  Few 
Real-time  imaging  No No No  Yes Potential Clinical Application on Contrast Echocardiography  Current Cardiology Reviews, 2010, Vol. 6, No. 1    27 
preclude the use of contrast, particularly in situations where 
the information is important and is either not available in any 
other way or could only be obtained with tests that have their 
own inherent complications. 
RELATION BETWEEN MCE AND SPECT 
PERFUSION 
  From the blood pool, 99mTc-sestamibi diffuses into the 
extravascular space and passively enters the myocyte before 
binding to the negatively charged mitochondrial membrane. 
Its retention within the myocyte, therefore, is dependent on 
intact mitochondrial function. Up to about two times normal 
flow, the myocardial uptake of 99mTc-sestamibi during 
exogenously induced hyperemia is determined by flow to 
that region. The relative distribution of 99mTc-sestamibi in 
various myocardial beds, therefore, reflects differential blood 
flow to those beds. Consequently, the presence of a 
perfusion mismatch during hyperemia indicates the presence 
of physiologically significant coronary stenosis. During rest, 
99mTc-sestamibi imaging provides information not only on 
baseline flow but also myocyte viability. Necrotic areas do 
not retain 99mTc-sestamibi and demonstrate reduced uptake. 
In comparison, absent or reduced contrast enhancement is 
seen within necrotic regions on MCE because of reduced 
myocardial blood volume consequent to microvascular 
disruption, plugging, and obliteration [12]. Regions with 
these patterns have been shown to demonstrate lack of 
recovery of function despite the presence of open infarct-
related arteries [13]. 
MYOCARDIAL CONTRAST ECHOCARDIOGRAPHY 
AS A TECHNIQUE OF MYOCARDIAL PERFUSION 
  Unlike other tracers used for assessing myocardial 
perfusion, MB used during MCE reside entirely within the 
vascular space. They do not enter the extravascular space or 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Power Modulation Imaging. In Power Modulation Imaging two consecutive pulses with identical shape but a twofold difference in 
amplitude are sent out and result in identical reflections from cardiac tissue, other than the expected twofold difference in amplitude. The 
smaller pulse is then multiplied by two and subtracted from the larger one, resulting in zero signal. The same two pulses, when reflected by 
nonlinear MB, produce signals of different shape and amplitude. Amplifying the smaller pulse and subtracting it results in a non-zero signal.  
Table 3.  Contraindications to the Use of Optison, Definity or Sonovue 
- Intra-arterial injection 
- Right-to-left, bi-directional, or transient right- to-left cardiac shunts 
- Worsening or clinically unstable congestive heart failure 
- Acutemyocardial infarction or acute coronary syndromes 
- Ventricular arrhythmias or high risk for arrhythmias due to QT prolongation 
- Respiratory failure, as manifest by signs or symptoms of carbon dioxide retention or hypoxemia 
- Severe emphysema, pulmonary emboli or other conditions that cause pulmonary hypertension due to compromised pulmonary arterial vasculature 
- Hypersensitivity to perflutren, blood, blood products, or albumin.  28    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Bezante et al. 
are extracted by myocytes. After peripheral injection, MB 
mix with blood in the central circulation, and their 
concentration at any given time within a myocardial region 
of interest reflects the volume of blood within that region. 
When changes in myocardial blood flow (MBF) are 
regulated by changes in MBV (as occurs with dipyridamole, 
which causes vasodilation of the coronary microcirculation), 
relative US intensity ratios within different myocardial 
regions reflect relative ratios of both MBV and MBF in these 
regions. It is well known that in the presence of a stenosis, 
MBF remains constant until the stenosis is severe (> 85% of 
luminal diameter narrowing). MBF is maintained by vaso-
dilation and/or recruitment of <300-μm microvessels distal 
to the stenosis. Thus, it is accepted that at rest, MBV 
increases within the bed supplied by a stenotic artery. 
Because it causes vasodilation of all microvessels, it is also 
generally assumed that MBV is equal between beds supplied 
by stenosed and nonstenosed vessels during exogenous 
hyperemia. Since during exogenous hyperemia, MBV and 
flow are closely coupled, the ratios of video intensities from 
different beds have been demonstrated to reflect the ratios of 
MBF to those beds. 
STRESS PROTOCOL IN CLINICAL PRACTICE 
  Stress agent. The most commonly used stress agents are 
adenosine, dipyridamole, and dobutamine (Table 4). All 3 
agents have been widely used for pharmacologic stress-
TESTS [14-17]. Although different working mechanism, all 
agents have a high diagnostic value for detection of CAD. It 
is well known that MCE can define the presence of abnormal 
perfusion at rest and during pharmacologic stress in stable 
CAD subjects, with a high concordance between MCE and 
99mTc-sestamibi single photon emission computerized 
tomography (SPECT). Also, comparison of accelerated 
intermittent imaging at rest and with exercise to SPECT 
demonstrated a concordance of 76% to 92%. Several other 
studies assessed the accuracy of MCE and SPECT/ 
dobutamine stress echocardiography for detection of stable 
CAD. In general, there is a good agreement between 
techniques, ranging from 65% to 92%. Furthermore, the 
addition of MCE may improve sensitivity for detection of 
CAD over wall motion analysis during stress. MCE provides 
prognostic value in patients with stable CAD. Patients with 
normal perfusion have a better outcome than patients with 
normal wall motion, underscoring the value of incorporating 
MCE in stress echocardiography. 
MCE IN THE ISCHEMIC SYNDROMES 
  Currently, the diagnosis of acute ischemic syndromes 
(ACS) is based on the triad of clinical history, electro-
cardiography, and laboratory investigation. These methods, 
although useful, can often be nondiagnostic in this setting. 
Because MCE is the only technique that permits immediate 
assessment of wall motion and perfusion, it has a unique role 
in the diagnosis of ACS [18]. Myocardial contrast 
echocardiography allows quick evaluation of myocardial 
perfusion in the emergency department and may be used to 
triage patients into a low- or high-risk category. The value of 
MCE in ACS has been studied experimentally using coro-
nary balloon occlusions in pigs. MCE accurately reflects the 
decrease in myocardial perfusion during balloon occlusion 
compared with microsphere-derived MBF. Studies have also 
shown that during coronary occlusion the area at risk 
correlates closely with the contrast defect early after contrast 
flash destruction and that the plateau contrast defect 
identifies infarct size. Kamp et al. [19] were the first to 
report the sensitivity of MCE to detect perfusion defects in 
patients suspected of having acute myocardial infarction 
(AMI). With 1:1 end-systolic–triggered imaging, MCE 
perfusion defects were detected in 19 of 32 patients (59%) 
with Thrombolysis In Myocardial Infarction (TIMI) flow 
grade 0 before percutaneous transluminal coronary angio-
plasty. The sensitivity of MCE tended to decrease when 
patients had better TIMI flow and inferior infarctions (20%), 
whereas the sensitivity of MCE in patients with an anterior 
coronary artery occlusion Is high (88%). Other studies 
assessing the potential of MCE to ACS also reported high 
sensitivities, comparable with those of standard echo-
cardiography and SPECT. In addition, MCE appears to have 
important prognostic value in patients presenting to the 
emergency department with acute chest pain [20]. Besides 
detection of acute ischemic heart disease, MCE may play a 
pivotal role in prediction of functional recovery in patients 
after ST-segment elevation myocardial infarction. The 
severity of myocardial damage is currently mainly estimated 
by enzymatic damage and wall motion score, whereas 
Table 4.  Stress Protocol in Clinical Practice 
  HR  BP  Scan  Regional and global function 
    Normal  response  Ischemic  response 
Dobutamine Increase  Increase 
systolic/ 
diastolic BP 
Difficult  Increase function and velocity of 
contraction compared with rest 
and usually with low dose; 
Greater decrease in ESV, marked 
increase in EF 
Decrease function and velocity of contraction 
compared with low dose; may be less 
compared with rest; Often same as normal 
response, rarely, ischemia produces decreased 
EF; cavity dilatation rarely occurs 
Vasodilator: 
Dipyridamole 
/Adenosine 
Reduction  Decrease  
systolic/ 
diastolic BP 
Easier  Increase function compared with 
rest; Decrease in ESV, increase in 
EF 
Decreased function compared with rest; Often 
same as normal response; occasionally, 
ischemia produces decreased EF; cavity 
dilatation rarely occours. Potential Clinical Application on Contrast Echocardiography  Current Cardiology Reviews, 2010, Vol. 6, No. 1    29 
recovery of myocardial function is importantly dependent on 
reflow of blood to the risk area [21]. The presence of reflow 
after coronary angioplasty is suggested by resolution of chest 
pain and the degree of resolution of ST-segment elevation 
but can be visualized by MCE. Kloner [22] was the first to 
demonstrate the deleterious effect of no-reflow on clinical 
outcome. Later, it was shown that the presence of no-reflow 
on MCE after AMI related to absence of preinfarction 
angina, number of Q waves, wall motion score at presen-
tation, TIMI flow grade 0, the size of the area at risk, and the 
occlusion status of the culprit artery [23]. Conversely, intact 
microvasculature after AMI (reflow), is a positive predictor 
of functional recovery [24]. Patients without microvascular 
dysfunction on MCE have less enzymatic elevation, better 
functional performance, better recovery of global and regio-
nal wall motion, less remodeling, and better survival 
independent of other predictors [25, 26]. 
  The ability of MCE to predict functional recovery is 
comparable to that of cardiovascular magnetic resonance 
imaging [27]. Thus the existing literature suggests that MCE 
has important additional value for diagnosis and risk 
stratification in patients with acute ischemic heart disease. 
The presence of a region of no-reflow is important in the 
decision of therapeutic strategy to predict the severity and 
duration of left ventricular dysfunction in the early stage of 
an myocardial infarction. MCE with no reflow detect clinical 
congestive heart failure in the early phase of the necrotic 
event. The higher frequency of early congestive heart failure 
in patients with no-reflow is still not clear. It seems that the 
no reflow phenomenon, the culprit lesion reflecting the size 
of the risk area, and age are related to early congestive heart 
failure [28]. The main reason of standing heart failure seems 
due to the larger area of infarction in patients with MCE no 
reflow than in those with MCE reflow; thus, it may take 
longer for the left ventricle to adapt to a larger infarction.  
MCE TO DETECT TARGET ORGAN DAMAGE 
  The study by Aggeli et al. [29] demonstrated the value of 
exercise test is the most widely used technique for the 
assessment of CAD, but it has a relatively low sensitivity 
and specificity compared with imaging techniques such as 
stressechocardiography SPECT imaging. Systemic hyper-
tension is a strong risk factor for CAD, but the prevalence of 
CAD in such patients is moderate. 
  An exercise test is the most widely used technique for the 
assessment of CAD, but it has a relatively low sensitivity 
and specificity compared with imaging techniques such as 
stress echocardiography and SPECT imaging. 
  Stress echocardiography is excellent for the assessment 
of CAD, but its sensitivity tends to be compromised in 
patients with significant left ventricular hypertrophy (LVH). 
Perfusion techniques like SPECT may suffer from low 
specificity, because hypertensive patients may have 
microvascular disease in the absence of large vessel CAD 
and often asymetrical LVH, which result in a relative 
difference in tracer uptake leading to apparent perfusion 
abnormalities even in the absence of microvascular disease 
and CAD. The MCE in this scenario is an ideal technique 
[30]. Perfusion defect in the presence of vasodilator stress 
almost always occurs when there is significant epicardial 
coronary stenosis. Microvascular disease is manifested as 
delayed MB filling of the myocardium after a destructive 
phase. These differential effects on the kinetics of MCE and 
differential manifestation as a result may allow MCE to 
accurately classify patients with and without CAD as 
opposed to microvascular disease. In the study by Aggeli et 
al. MCE was equivalent to SPECT for the detection of CAD 
with a tendency toward higher sensitivity of MCE compared 
with SPECT. The latter is likely because MCE, by virtue of 
its superior spatial resolution compared with SPECT, is 
likely to identify mild subendocardial ischemia due to CAD 
more effectively. 
MCE IN HEART FAILURE 
  MCE is a bedside technique that can be used early in 
patients presenting with acute heart failure (AHF) to rapidly 
assess LV function (regional and global) and perfusion (rest 
and stress) [31]. Demonstration of normal resting myocardial 
perfusion in patients with AHF indicates viable myocardium 
[32]. The presence of significant reversible myocardial 
perfusion defects in these patients establishes the diagnosis 
of flow-limiting CAD and should prompt the attending 
physician to plan for urgent coronary arteriography and 
revascularization [33]. Coronary arteriography may not be 
warranted in patients with no demonstrable myocardial 
perfusion defects. However, even in the absence of obvious 
myocardial perfusion defects, determination of MBF reserve 
may help to predict the outcome of patients with heart 
failure. These findings are likely to affect the routine practice 
of all AHF patients in our institution undergoing coronary 
arteriography. 
CONCLUSIONS 
  Myocardial contrast echocardiography is a relatively 
simple technique for imaging of myocardial perfusion that 
should be used in different clinical settings. The ability of 
MCE to provide a comprehensive assessment of cardiac 
structure, function, and perfusion is likely to make it the 
technique of choice for non-invasive cardiac imaging. MCE 
is accurate in distinguishing different patterns of myocardial 
perfusion suggesting a potential risk-stratification technique 
in subjects without a prior history of CAD or clinical 
features suggestive of an ACS. 
ABBREVIATION 
ACS =  Acute  coronary  sindrome 
AHF  =  Acute heart failure 
AMI  =  Acute myocardial infarction 
CAD  =  Coronary artery disease 
LVH  =  Left ventricular hypertrophy 
MB =  Microbubbles 
MBF  =  Mycardial blood flow 
MBV  =  Mycardial blood volume 
MCE  =  Mycardial contrast echocardiography 
MI =  Mechanical  index 30    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Bezante et al. 
SPECT  =  Single photon emission computerized 
tomography 
US =  Ultrasound 
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